In Paris Essilux down after the accounts, analysts divided between optimists and cautious | EUROtoday

Listen to the audio model of the article

(Il Sole 24 Ore Radiocor) – Essilorluxottica fell sharply on the Paris Stock Exchange (CAC 40), following the discharge of revenues for the primary quarter of 2026, though they’re in double digits at fixed alternate charges. The numbers, nonetheless, are outcomes in step with expectations, whereas buyers anticipated extra. In addition they continue to be doubts concerning the demand for sensible glasses and above all on the margins that these merchandise assure for the group.

In element, Essilorluxottica closed the January-March interval with a turnover of seven.12 billion, a rise of 10.8% at fixed alternate charges or 4.1% at present alternate charges. North America recorded a double-digit developmentwhereas all different geographical areas reported high-single digit development. In the convention name Stefano Grassi, the monetary director, specified that theMiddle Eastern space is virtually negligible for the group and threw water on the hearth on any manufacturing bottlenecks that might be created because of the warfare, as occurred within the post-covid interval.

Francesco Milleri and Paul du Saillant, president and CEO and vice-CEO respectively, highlighted that the The group’s technique is more and more oriented in direction of med tech and science. Meanwhile this morning Essilux introduced theacquisition of Faroan Italian firm with over 20 years of expertise within the design, manufacturing and distribution of excessive precision CNC milling and diamond chopping equipment devoted to the eyewear and jewelery sectors. «The acquisition additional expands the vertical integration mannequin of EssilorLuxottica, increasing its technological capabilities,” the corporate defined.

Analysts are divided between optimists and pessimists and above all they’re confused concerning the multiples to use to the corporatenot realizing whether or not to think about it a luxurious firm or somewhat a med-tech or expertise firm. «The technique of accelerating on medtech could also be considerable, however in recent times it’s the sector that has recorded the worst performances», highlighted an analyst. Meanwhile Berstein continued to be cautious (Market-Perform with a goal of 185 euros) on the shares, persevering with to query the way forward for the group and above all of the efficiency of the so-called sensible glasses, which for now, in accordance with the enterprise home, assure modest margins and are additionally topic to the blows of unbridled competitors from giants comparable to Google and Apple. In brief, Bernstein highlighted, Essilux’s shares might be the topic of sooner or later fluctuations based mostly on technological improvements introduced available on the market each from the group and from the competitors.

For the enterprise home, the group «within the first quarter of 2026 EssilorLuxottica finds itself in a fragile scenario. The conventional eyewear enterprise continues to develop, however on the identical time the expansion of wearable units appears to have slowed down”, even if the company did not provide exact numbers in this regard. However, Bernstein explains that «a faster growth of wearable devices would have raised concerns among investors about the margin dilution observed in the fiscal year 2025 balance sheet. However, too slow growth would have called into question the high expectations for the short term incorporated in the consensus estimates.” For Bernstein «iThe first quarter of 2026 doesn’t resolve the controversy. Such readability may solely arrive in 2027.” In the convention name, nonetheless, Grassi reassured that as increasingly AI Glasses are bought, the margins of those merchandise may even have a tendency to enhance.